Cipla announced that its wholly owned US subsidiary, InvaGen Pharmaceuticals, has received a No Action Indicated (NAI) classification from the US Food and Drug Administration (US FDA) for its manufacturing facility in Hauppauge, Long Island, New York.
The classification follows a US FDA inspection conducted between October 19 and October 22, 2026. The NAI status indicates that the inspection did not identify conditions requiring regulatory action.
The outcome is expected to support manufacturing operations and continuity of product supplies from the facility across the North American market.
Cipla's North America business reported revenue of USD 172 million in Q2 FY27. The company also reported a net cash balance of INR 9,823 crore as of September 30, 2026.
The regulatory outcome provides clarity on the compliance status of InvaGen's Hauppauge manufacturing facility and supports Cipla's operations in the US market.
Last news about this category
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy